PPAR-α/δ agonist
Elafibranor
Brand names: Iqirvo
Adult dose
Dose: 80mg PO OD
Route: Oral
Frequency: OD
Clinical pearls
- Primary biliary cholangitis with inadequate response to UDCA — second-line per EASL PBC guidelines
- NICE TA evaluation; specialist hepatology
- Conditional EMA approval 2024
Contraindications
- Decompensated cirrhosis
- Pregnancy
- Hypersensitivity
Side effects
- Weight gain
- Abdominal pain
- Diarrhoea
- Nausea
- Myalgia / myopathy
- Bone fracture risk
- Hepatotoxicity
Interactions
- OATP1B1 substrates
- Statins (myopathy risk)
Monitoring
- LFTs (ALP, bilirubin, ALT)
- Weight
- Bone health (long-term)
- Lipids
Reference: BNF; EASL PBC clinical practice guidelines; NICE TA evaluation; SmPC; https://bnf.nice.org.uk/drugs/elafibranor/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Lymphadenopathy Workup · NICE NG12; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023